Immune Design appoints Susan Kelley to board of directors
Dr. Kelley has more than 25 years' experience in oncology and immunology drug development.
She currently serves as independent consultant to the pharmaceutical and biotechnology industries in the field of oncology drug development and holds positions on the boards of directors of several companies, including ArQule and Cerulean Pharma.
From 2008 to 2011, Dr. Kelley served as Chief Medical Officer of the Multiple Myeloma Research Consortium and its sister organization, the Multiple Myeloma Research Foundation, where her leadership responsibilities included the strategic design and management of clinical trials conducted by a consortium of leading myeloma clinical research centers in North America.
Prior to the Multiple Myeloma Foundation, Dr. Kelley worked with Bayer Healthcare Pharmaceuticals and then Bayer-Schering Pharma from 2001 to 2008 as Vice President, Global Clinical Development and Therapeutic Area Head — Oncology.
She led the Bayer team responsible for the development and worldwide regulatory approval of Nexavar (sorafenib) in kidney cancer and liver cancer. From 1987 to 2001, she worked with Bristol-Myers Squibb in Oncology and Immunology drug development.
Dr. Kelley received an M.D. from Duke University School of Medicine. ■
LATEST MOVES FROM Washington
- CTI BioPharma appoints Laurent Fischer as chairman
- Expedia appoints Mark Okerstrom as CEO
- Kelley Hall joins Nordstrom as senior vice president
- Apptio appoints Kathleen Philips to board
- Timberland Bancorp appoints Kathy D. Leodler to board
More inside POST